Multiple sclerosis (MS) is a progressive inflammatory, and chronic demyelinating, neurodegenerative disease of central nervous system (CNS) . Autoimmune responses to myelin and other CNS antigens mediated by cluster of differentiation 4 (CD4 + ) T cells are critical for initiation and progression of disease. Migration of autoimmune T cells from the peripheral lymph organs into CNS parenchyma leads to inflammation, demyelination and damage of axonal cytoskeleton, which manifest in decreased impulse conduction velocity of motor and sensory nerves. Myelin and axonal pathology causes motor, sensory and autonomic nerve dysfunction, including optic nerve damage leading to double or distorted vision; paresis and paralysis of extremities, painful sensations, and bladder sphincter dysfunction, manifested as bladder incontinence. Gray matter pathology in cortical and subcortical regions, including cerebellum and hippocampus underlies cognitive and behavioral dysfunction consisting of memory deficits, depression, and ataxic gait and tremor.
Multifaceted cellular and molecular mechanisms involved in autoimmune-mediated inflammation, demyelination, and subsequent degeneration of axonal cytoskeleton as well as neuronal cell dysfunction and demise, have been researched in experimental autoimmune encephalomyelitis (EAE) . With the development of new EAE models, significance of EAE in MS studies continues to be reexamined and the importance of similarity between two diseases to be highlighted (Skundric, 2005) . This autoimmune experimental model is regularly used in development and preclinical testing of MS therapy aimed at treating or ameliorating autoimmune responses observed in MS, with an ultimate goal to cure or diminish tissue damage and support axonal regeneration and repair. Multiple sclerosis is a chronic, progressive, debilitating disease, which often takes a relapsing-remitting course. Relapses and remissions of disease correspond with reappearance and clearance of inflammatory CD4 + T cells in CNS, respectively as suggested from clinical analysis, MRI data, and histopathology (Giovannoni et al., 2001; Frischer et al., 2009 ). There is a relative lack of EAE models resembling clinical course, clinical findings and histopathology of CNS inflammatory infiltration, demyelination and axonal degeneration, observed in relapsing remitting MS (RRMS). In search for regulatory mechanisms underlying autoimmune CD4 + Th1 cell recirculation between CNS and peripheral lymph organs and re-infiltration underlying EAE relapse, we investigated regulation of relapses in autoimmune responses induced by immunization with immunodominant epitope of myelin oligodendrocyte glycoprotein, a peptide p35-55 -(AQP4 -) relapsing neuromyelitis optica (NMO) and other NMO-spectrum disease (NMOSD) (Reindl et al., 2013) . In attempts to study EAE, which more closely resemble RRMS clinical course, we originally created a model of relapsing-remitting EAE in response to MOG (Skundric, 2003) . Histopathology of CNS lesions in relapsing H-2 b/s mice resembles human MS pathology of small infiltrates, which are found scattered throughout brain parenchyma and extensive infiltration in meninges. We observed an important similarity of specific pattern of demyelination in relapsing H-2 b/s mice, resembling MS lesion. Most pronounced decrease in levels of myelin-associated glycoprotein (MAG) in MS lesions, which was suggestive of oligodendrocyte dysfunction and/or damage was detected in CNS of relapsing H-2 b/ s but not in H-2 b mice. Preferential loss of MAG was unanticipated in lesions induced by autoimmune responses to a different myelin protein, which was MOG . Similar pattern of demyelination was reported in the MS lesion subtype III, where profound loss of MAG functions as a guide of a distal oligodendrogliopathy. Depletion of MAG correlated well with that of medium chain of neurofilament (NF160) and sharp elevation of poly (ADP-ribose) polymerase (PARPp85). Neurofilaments are the major type of intermediate filaments in adult neurons, while a nuclear enzyme PARP regulates DNA repair. Profound depletion of MAG, decrease of NF160 axonal neurofilament and sharp elevation of PARPp85 suggested axonal dysfunction and irreversible apoptosis, respectively and correlated with severe relapsing disease in H-2 b/s mice (Figure 1 ) (Skundric et al., 2008) .
To explore chemotactic mechanisms underlying a CD4 + T cell predominated inflammatory lesions in relapsing H-2 b/s mice, we investigated a T cell chemotactic factor, a cytokine interleukin (IL)-16 as likely candidate, though to our knowledge its relationship with MS and EAE had not been explored or suggested by others. A CD4 co-receptor specific ligand, IL-16, governs trafficking and biological properties of CD4 + T cells irrespective of cell activation state, through p56lck mediated signaling, which leads to the rearrangement of intracellular cytoskeleton. It was demonstrated that IL-16 induces preferential migration of CD4 + Th1 compared to Th2 cells. A cytokine IL-16 controls key biological properties of CD4 + T cells including cell activation, CD25 (IL-2Rα) expression, MHC class II molecule expression, co-stimulatory and inhibitory molecules expression, production of Th1, Th2 and immune modulatory cytokines and cooperation with antigen presenting cells (APC) including macrophages, dendritic cells (DC) and microglia, and communications with B and T cells, which are all of critical importance for the initiation and regulation of CD4 + Th1 immune responses to myelin and other antigens. A cytokine IL-16 also regulates migration of a T regulatory (Treg) CD4 + CD25 + FOXP3 + cells, expansion of CD4 + CD25 + T cells in long-term cultures propagated with IL-2, and de novo induction of FOXP-3 transcription. This cytokine modulates migration induced by chemokine receptor CCR5, which is expressed by activated cells including CD4 + Th1 cells, through cross-receptor desensitization between CD4 and CCR5, which are structurally and functionally interrelated. It also modulates chemokine receptors CXCR3 and CXCR4 induced migration, which are all implicated in pathogenesis of MS. A very important feature of IL-16 lies in the fact that this is a shared molecule between the immune and nervous systems. In nervous system, IL-16 impacts on homeostatic properties of neuronal and synaptic functions. IL-16 is highly conserved across species including human and mouse. Post mitotic cerebellar granule neurons (CGN) and neurons in hippocampus contain neuronal IL-16 (NIL-16), splice variant of immune IL-16, and express CD4 molecule. In a CD4 dependent manner, IL-16 supports cultured CGN survival. Finally, IL-16 contains postsynaptic density/disc large/zona ocludens-1 (PDZ) domains, which makes this cytokine a scaffolding protein and enables important interaction with other proteins, DNA or RNA. Such interactions are significant in pathogenesis of viral infection and malignant cell proliferation (Figure 2) . PDZ domain related functions of IL-16 bare great importance to complications of many disease-modifying therapies (DMT) of RRMS, which develop as a result of relative immune suppression or modulation. Those serious complications include increased susceptibility to viral infections and malignant cell transformation in DMT treated MS patients. Prospective IL-16 containing therapy would have unique potential to utilize PDZ domain mediated interactions in preventing common DMT complications in combination with DMT or as a single therapy. Neutralization of IL-16 was successful in treatment of MOG 35-55 induced relapsing-remitting EAE H-2 b/s mice. In this EAE therapy study, IL-16 specific antibody reversed paralysis, diminished CD4 + T infiltration, abrogated demyelination and axonal damage and supported re-myelination in relapsing EAE H-2 b/s mice. Administration of therapy as soon as onset of EAE occurred was pivotal for success of treatment. Repeated treatments at every relapsing episode had beneficial protective effect (Skundric et al., 2005b) .
In relapsing-remitting MOG 35-55 induced EAE in (B6 x SJL) F1 (H-2 b/s ) mice, intra-CNS production of IL-16 correlates with extensive CD4 + T cell infiltration, increased levels of active caspase-3, accompanied by phosphorylation of axonal cytoskeleton, which all peak during relapses and in chronic progressive disease. IL-16 and CD4 were co-precipitated from CNS of relapsing H-2 b/s mice. EAE data suggest active caspase-3 mediated release of bioactive IL-16 from infiltrating CD4 + T cells, which supports progression of local inflammation by specifically enhancing trafficking of additional CD4 + T cells (Skundric et al., 2005a In RRMS similarly to EAE relapse, peak levels of IL-16 and active caspase-3 correlated with CD4 + T cell infiltration and was found in lesions. Apart from lesions, bioactive IL-16 was located in normal appearing white matter (NAWM) and normal appearing grey matter (NAGM) in RRMS brain and spinal cord. In the MS brain, highest levels of IL-16 were detected in chronic lesions, followed by subacute and acute. Conversely, in spinal cord, acute lesions contained highest levels of IL-16. More robust increase of IL-16 was noted in spinal cord compared to brain NAWM. Sharp increase of pro-IL-16 was found in NAGM in RRMS brain (Skundric et al., 2006) . Data propose regional differences in IL-16 regulation in CNS lesions between brain and spinal cord and a role of bioactive and pro-IL-16 in pathology of NAWM and NAGM in RRMS. Corresponding to our findings of elevated IL-16 levels in situ, raised levels of IL-16 were detected in serum of MS patients. Following IFN-β1a therapy, IL-16 serum levels decreased. Authors suggested that IL-16 may serve as a biomarker for MS responses to IFN-β1a therapy (Nischwitz et al., 2014) .
Results from RRMS and corresponding data from MOG induced relapsing EAE in H-2 b/s mice suggest a role of IL-16 in neuron-immune cell communications in gray matter lesions including cerebellum and hippocampus, and in adjacent NAGM and NAWM. Grey matter lesions underlie cognitive deficits observed in MS (Howell et al., 2014) . Emerging role of IL-16 in immune regulation of relapsing EAE and RRMS, which is supported by experimental data concordant with MS clinical and histopathological evidence, underscores potential of IL-16 for development of more specifically targeted, a CD4 + Th1 cell selective therapies for RRMS and possibly other progressive inflammatory and neurodegenerative diseases. Delineating mechanisms responsible for selective enhancement of migration specific for CD4 + T cell subsets is critical for better understanding and subsequent therapy of MS and other chronic inflammatory and demyelinating diseases. Broader, greater insights into a mechanisms of IL-16 in regulation of other chronic and progressive inflammatory, demyelinating and neurodegenerative diseases holds promise for development of new therapeutic approaches aimed at protection of neurons and repair of axonal function. A MOG 35-55 induced relapsing-remitting EAE in H-2 b/s mice enables insights into local regulation of pathology of myelin forming cells in CNS, oligodendrocytes, especially in studies aimed at understanding how to overcome inhibitory signals of re-myelination in CNS and help in developing therapies to foster re-myelination. This EAE model may be also employed in studies of oligodendroglial damage, which occurs as result of metabolic, vascular, or toxic insults (Skundric et al., 2015) .
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